Lawrence Parsons, APRN
Nurse Practitioner · East Hampton, CTNPI 1972021244
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 399 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 18.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,279, more than ten times the $250 reported in 2021. Among nurse practitioner clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 399 payments — averaging $21.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Takeda Pharmaceuticals U.S.A., Inc.$753
- Phathom Pharmaceuticals, Inc.$667
- Ardelyx, Inc.$599
- Johnson & Johnson$521
- plus $3K from 26 others
What the payments were for
- Food & beverage$8,410100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 91 | $1,586 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 75 | $1,442 |
| Takeda Pharmaceuticals U.S.A., Inc. | 28 | $753 |
| Phathom Pharmaceuticals, Inc. | 29 | $667 |
| Ardelyx, Inc. | 25 | $599 |
| Johnson & Johnson | 25 | $521 |
| Gilead | 24 | $435 |
| Madrigal Pharmaceuticals | 9 | $327 |
| Ironwood Pharmaceuticals, Inc | 11 | $242 |
| Pfizer | 12 | $221 |
| Bristol Myers Squibb | 9 | $210 |
| Lilly USA, LLC | 8 | $174 |
| Fresenius Kabi USA, LLC | 6 | $153 |
| Exact Sciences | 5 | $145 |
| Intercept Pharmaceuticals, Inc. | 5 | $123 |
| Braintree Laboratories, Inc. | 6 | $114 |
| QOL Medical, LLC | 2 | $90 |
| Ferring Pharmaceuticals Inc. | 5 | $87 |
| Alnylam Pharmaceuticals Inc. | 3 | $74 |
| Celltrion USA Inc. | 3 | $67 |
| Mallinckrodt Hospital Products Inc. | 2 | $49 |
| Boehringer Ingelheim | 2 | $41 |
| Aimmune Therapeutics, Inc. | 2 | $41 |
| Regeneron Healthcare Solutions, Inc. | 2 | $39 |
| Cumberland Pharmaceuticals, Inc. | 2 | $37 |
| Novo Nordisk | 1 | $33 |
| Biocon Biologics Inc | 1 | $30 |
| Redhill Biopharma Inc. | 2 | $29 |
| Sanofi | 1 | $25 |
| Nestle Healthcare Nutrition Inc. | 1 | $21 |
| Evoke Pharma, Inc. | 1 | $17 |
| Amgen | 1 | $16 |
How this compares
$8,410 in reported general payments places this provider in the 95th percentile of 1,162 nurse practitioner providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 107 | $130,895 |
| XifaxanRifaximin | 28 | $76,958 |
| CreonLipase/Protease/Amylase | 16 | $50,370 |
| TrulancePlecanatide | 18 | $19,053 |
| Mesalamine | 40 | $16,024 |
| Dexlansoprazole DrDexlansoprazole | 39 | $13,999 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 220 | $13,829 |
| SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag | 85 | $10,523 |
| Esomeprazole Magnesium | 76 | $8,563 |
| Lubiprostone | 20 | $5,173 |
| Pantoprazole Sodium | 445 | $4,864 |
| PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C | 30 | $4,475 |
| Omeprazole | 295 | $4,466 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 19 | $3,075 |
| CholestyramineCholestyramine (With Sugar) | 22 | $2,915 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Creon | $1,586 | $181,264123 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance, Plenvu | $1,442 | $100,48676 claims |
| Braintree Laboratories, Inc.Suflave, Sutab | $114 | $13,598104 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $87 | $2,64015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,162 nurse practitioner providers in Connecticut.
Other nurse practitioner in East Hampton
- Lindita VincaCheshire$427K
- Catherine MilnePlymouth$361K
- Michele NovellaDanbury$331K
- Tiffany RydzNewtown$49K
- Paul FidrychNorwich$23K
- Priscilla QuilterNorwich$21K
- Kimberly BoldonMiddletown$19K
- Emma RobinsonStamford$17K
- Janice TavaresBridgeport$17K
- Kelly WilberWaterbury$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.